Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia | Zendy

Shan L. Maude | Zendy; Noelle V. Frey | Zendy; Pamela A. Shaw | Zendy; Richard Aplenc | Zendy; David M. Barrett | Zendy; Nancy Bunin | Zendy; Anne Chew | Zendy; Vanessa Gonzalez | Zendy; Zhaohui Zheng | Zendy; Simon F. Lacey | Zendy; Yolanda D. Mahnke | Zendy; J. Joseph Melenhorst | Zendy; Susan R. Rheingold | Zendy; Angela Shen | Zendy; David T. Teachey | Zendy; Bruce L. Levine | Zendy; Carl H. June | Zendy; David L. Porter | Zendy; Stephan A. Grupp | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Author(s) -

Shan L. Maude,

Noelle V. Frey,

Pamela A. Shaw,

Richard Aplenc,

David M. Barrett,

Nancy Bunin,

Anne Chew,

Vanessa Gonzalez,

Zhaohui Zheng,

Simon F. Lacey,

Yolanda D. Mahnke,

J. Joseph Melenhorst,

Susan R. Rheingold,

Angela Shen,

David T. Teachey,

Bruce L. Levine,

Carl H. June,

David L. Porter,

Stephan A. Grupp

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1407222

Subject(s) - chimeric antigen receptor , immunology , medicine , cytokine release syndrome , transplantation , oncology , immunotherapy , immune system

Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research